Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
NCT03468153
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
BIOLOGICAL:
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Sponsor
Ruijin Hospital
Collaborators
[object Object]